GSK Cervarix Clears Landmark FDA Vaccine Committee with Okay for Novel Adjuvant

GlaxoSmithKline's two-year delay to do more safety work on the vaccine and specifically on the AS04 adjuvant gets the sponsor past one major milestone with a strong vote on safety for use in girls and young women.